Page 9 of 15 · 360 questions tagged semaglutide.
The specifics, since they change the answer: liraglutide · semaglutide. The comparison I want does not seem to exist anywhere in a form I can evaluate. I have read…
The receptor pharmacology I can follow; the in vivo translation is where I lose the thread. The empirical answer seems settled. The explanation does not. If the…
What I am working with: STEP 8 · cagrilintide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
Conditions: SUSTAIN-6 · liraglutide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result,…
My background is chemistry rather than physiology, which may explain where I am stuck. This has the shape of a fact but I cannot find its origin. What I found instead…
Details up front: ESSENCE · orforglipron. I would rather be corrected now than propagate something wrong. I am specifically not interested in a testimonial; I am…
What I am working with: STEP 8 · cagrilintide. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary sources all citing…
Setup, so nobody has to ask: SURMOUNT-1 · a GLP-1 receptor agonist. This has the shape of a fact but I cannot find its origin. What I found instead were three…
The particulars: STEP 4 · ecnoglutide. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably comfortable…
Details up front: SURPASS-2 · dulaglutide. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the evidence…
Details up front: cagrilintide · retatrutide. I want to know what the trade-off actually is rather than which option is fashionable. I would rather have a defensible…
The particulars: SUSTAIN-6 · survodutide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…
I completed two telehealth intakes last month to compare them before committing. The first took about forty minutes, included a video call with a nurse practitioner,…
Numbers first: a GLP-1 receptor agonist · mazdutide. I want to know what the trade-off actually is rather than which option is fashionable. I would rather have a…
For reference: liraglutide · tirzepatide. I am trying to choose between two options that are usually discussed as though only one exists. I am not optimising for…
I have been reading certificates of analysis and I keep seeing the product name written three different ways: "semaglutide", "semaglutide sodium", and once…
Conditions: ecnoglutide · retatrutide. I would like the axes of comparison first and the recommendation second. I have tried the first option and it works; the…
What I am working with: SURMOUNT-1 · cagrilintide. I have read the primary source rather than the summary, which has left me with more questions. I understand the…
The case in front of me: STEP 1 · liraglutide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…
My endocrinologist's office submitted a prior authorisation for semaglutide 2.4 mg eleven days ago. The portal says "in review". When I call the plan, the first-line…
The case in front of me: STEP 5 · oral semaglutide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a…
I have two third-party reports in front of me. Both say "identity confirmed by ESI-MS" and both include a spectrum, but the spectra look nothing like the single clean…
The specifics, since they change the answer: SURMOUNT-4 · semaglutide. I have the document in front of me and I can read the numbers. What I cannot do is interpret…
Stated plainly: SURMOUNT-5 · a GLP-1 receptor agonist. I have read the primary source rather than the summary, which has left me with more questions. I understand the…